Journal
CANCERS
Volume 13, Issue 24, Pages -Publisher
MDPI
DOI: 10.3390/cancers13246297
Keywords
klotho; KL1; sKL; tumor suppressor; pancreatic cancer; PDAC
Categories
Funding
- Sami and Tova Sagol Foundation for the Study of Aging
- Margaret Stultz foundation for Pancreatic Cancer Research
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Ministerio de Ciencia e Innovacion 'Proyectos I+D+I 2019' [PID2019-104034RB-I00]
- TASMC excellence fund
Ask authors/readers for more resources
The study demonstrated that klotho acts as a tumor suppressor in pancreatic ductal adenocarcinoma, with DNA methylation being correlated with patient survival. The findings suggest that sKL could serve as a therapeutic agent for pancreatic cancer.
Simple Summary We aimed to study the role of the anti-aging protein klotho and its secreted isoform, sKL, in pancreatic cancer. Three in vivo models, including a novel genetic mouse model and bioinformatics analyses, indicated klotho as a tumor suppressor in pancreatic ductal adenocarcinoma, and unveiled a unique klotho DNA hypermethylation pattern in pancreatic tumors. These results possess significant prognostic value, and further suggest that sKL may serve as a therapeutic agent for pancreatic ductal adenocarcinoma. Klotho is an anti-aging transmembrane protein, which can be shed and can function as a hormone. Accumulating data indicate that klotho is a tumor suppressor in a wide array of malignancies, and designate the subdomain KL1 as the active region of the protein towards this activity. We aimed to study the role of klotho as a tumor suppressor in pancreatic ductal adenocarcinoma (PDAC). Bioinformatics analyses of The Cancer Genome Atlas (TCGA) datasets revealed a correlation between the survival of PDAC patients, levels of klotho expression, and DNA methylation, and demonstrated a unique hypermethylation pattern of klotho in pancreatic tumors. The in vivo effects of klotho and KL1 were examined using three mouse models. Employing a novel genetic model, combining pancreatic klotho knockdown with a mutation in Kras, the lack of klotho contributed to PDAC generation and decreased mousece survival. In a xenograft model, administration of viral particles carrying sKL, a spliced klotho isoform containing the KL1 domain, inhibited pancreatic tumors. Lastly, treatment with soluble sKL prolonged survival of Pdx1-Cre; Kras(G12D/+);Trp53(R172H/+) (KPC) mice, a model known to recapitulate human PDAC. In conclusion, this study provides evidence that klotho is a tumor suppressor in PDAC. Furthermore, these data suggest that the levels of klotho expression and DNA methylation could have prognostic value in PDAC patients, and that administration of exogenous sKL may serve as a novel therapeutic strategy to treat PDAC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available